-
H.C. Wainwright Reiterates Buy Rating on Opko Health (OPK)
-
OPKO Health's ModeX begins phase 1 trial of COVID-19 prevention drug
-
OPKO Health (OPK) Tops Q4 EPS by 3c, provides guidance
-
H.C. Wainwright Reiterates Buy Rating on Opko Health (OPK)
-
OPKO Health and Entera Bio expand partnership for oral PTH tablet
-
JPMorgan Starts Opko Health (OPK) at Neutral
-
Jefferies Downgrades Opko Health (OPK) to Hold
-
OPKO Health (OPK) Tops Q3 EPS by 9c
-
OPKO's ModeX partners with Regeneron on multispecific antibodies
-
OPKO Health's ModeX starts cancer drug trial
-
OPKO Health (OPK) Misses Q2 EPS by 8c
-
OPKO Health and Entera Bio abstract selected for ESPEN Congress
-
NextPlat Corp (NXPL) Issues Interim CEO Update Shareholder Letter
-
OPKO Health (OPK) and Entera Bio (ENTX) Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation
-
OPKO Health's (OPK) ModeX Therapeutics Forms Scientific Advisory Board
-
OPKO Health (OPK) Misses Q1 EPS by 1c
-
JPMorgan Starts Opko Health (OPK) at Neutral
-
H.C. Wainwright Reiterates Buy Rating on Opko Health (OPK)
-
OPKO Health (OPK) Announces $100 Million Increase to its Existing Share Repurchase Program
-
H.C. Wainwright Reiterates Buy Rating on Opko Health (OPK)
-
OPKO Health (OPK) and Entera Bio (ENTX) Enter into Collaboration Agreement
-
H.C. Wainwright Reiterates Buy Rating on Opko Health (OPK)
-
Labcorp (LH) Announces Acquisition of Select Assets of BioReference Health's Innovative Oncology and Related Clinical Testing Services Businesses
-
OPKO Health (OPK) Tops Q4 EPS by 9c
-
Increasing unusual call option volume: LFMD GDRX GFI OPK ODD PRMB DAVE SLG MO MAXN
-
H.C. Wainwright Reiterates Buy Rating on Opko Health (OPK)
-
OPKO Health (OPK) Tops Q3 EPS by 12c
-
NextPlat Corp (NXPL) Secures Four-Year Extension of OPKO (OPK) Healthcare E-Commerce Program in China and Agrees to the Expansion of the Program into Japan
-
OPKO Health's (OPK) ModeX Therapeutics Secures $35M BARDA Supplement
-
H.C. Wainwright Reiterates Buy Rating on Opko Health (OPK)
-
Entera Bio Ltd. (ENTX) and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin Peptide Tablet Candidate
-
OPKO Health's (OPK) ModeX Therapeutics Appoints Dr. Giovanni Abbadessa as Chief Medical Officer as Pipeline Advances into Clinical Development
-
Piper Sandler Reiterates Overweight Rating on Opko Health (OPK)
-
H.C. Wainwright Reiterates Buy Rating on Opko Health (OPK)
-
OPKO Health (OPK) Tops Q2 EPS by 9c
-
OPKO Health (OPK) Announces $100M Share Buyback
-
Opko Health (OPK) PT Lowered to $3 at Piper Sandler

